4
Participants
Start Date
May 17, 2017
Primary Completion Date
July 31, 2021
Study Completion Date
July 31, 2021
human fetal-derived Neural Stem Cells (hNSCs)
"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."
IRCCS Ospedale San Raffaele, Milan
Fondazione Italiana Sclerosi Multipla
OTHER
IRCCS San Raffaele
OTHER